유럽의 항체 탐색 시장 : 오퍼링별, 기술별, 국가별 - 분석과 예측(2025-2035년)

This report can be delivered in 2 working days.

Introduction to Europe Antibody Discovery Market

The Europe antibody discovery market is projected to reach $10.13 billion by 2035 from $3.23 billion in 2025, growing at a CAGR of 12.11% during the forecast period 2025-2035. The market for antibody discovery in Europe is developing quickly thanks to robust biomedical research ecosystems, cutting-edge engineering technologies, and growing automation and artificial intelligence adoption. The increasing demand for totally human and humanized antibodies is a significant development that reflects Europe's emphasis on reduced immunogenicity, safety, and specificity. Phage display, transgenic animal models, and glycoengineering are examples of platforms that support translational rigor in early-stage projects while facilitating the development of targeted medicines for autoimmune, infectious, and oncology disorders.

Simultaneously, European businesses are combining automation, AI-driven modeling, next-generation sequencing, and high-throughput screening to speed up antibody selection and optimization. Scalability and availability to specialized skills are being improved by a greater dependence on academic-industry partnerships and contract research companies. By expanding therapeutic potential through innovations in single-domain antibodies, antibody-drug conjugates, and bispecific antibodies, Europe is positioned for long-term growth even in the face of competition from gene and cell therapies.

Market Introduction

The European antibody discovery industry is emerging as a vital component of the global biologics ecosystem, bolstered by a solid foundation of university research, modern healthcare infrastructure, and a growing number of innovative biotech firms. A favorable environment for antibody discovery in oncology, immunology, infectious illnesses, and uncommon disorders is created by the presence of some of the top research institutes and pharmaceutical companies in the world in Europe. Antibodies have become the preferred therapeutic modality due to the growing demand for targeted and precision therapeutics, which has led to a continuous investment in early-stage discovery and platform innovation throughout the region.

The European market is distinguished by technological innovation. The desire to increase safety, specificity, and clinical success rates is driving the adoption of both completely human and humanized antibodies. Glycoengineering, transgenic animal models, and phage display are common discovery platforms, and automation, next-generation sequencing, and high-throughput screening are simplifying antibody identification and optimization. Simultaneously, machine learning and artificial intelligence are being included into discovery workflows to improve developability evaluation, affinity maturation, and target selection.

Strong cooperation between pharmaceutical corporations, biotechnology businesses, contract research organizations, and university institutions is another feature of the antibody discovery scene in Europe. Scalability and cost-effectiveness are made possible by the growing outsourcing of discovery tasks to specialist CROs. The European antibody discovery market is positioned for long-term growth and strategic significance due to ongoing innovation in discovery methods and supporting regulatory frameworks, despite obstacles such high development costs and competition from other modalities.

Market Segmentation:

Segmentation 1: By Offering

• Product
• Services

Segmentation 2: By Technology

• Phage Display Technology
• Hybridoma Technology
• Single B-Cell Technologies
• Transgenic Animal-based Methods
• Other Technologies

Segmentation 3: By Region

• Europe

Europe Antibody discovery Market Trends, Drivers and Challenges

Market Trends

• Accelerated adoption of AI and machine learning for target identification, antibody design, and lead optimization, reducing discovery timelines.
• Growing use of next-generation antibody formats such as bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and engineered fragments.
• Expansion of integrated, end-to-end discovery platforms combining wet-lab screening with computational biology.
• Rising reliance on CROs and specialized service providers for antibody discovery and early development.
• Increased focus on function-first and translational assays, including cell-based and disease-relevant screening models.

Key Market Drivers

• Strong and sustained demand for targeted biologics in oncology, autoimmune disorders, and chronic diseases.
• Increasing R&D investments by pharmaceutical companies and venture funding for antibody-focused biotech startups.
• Technological advancements in single-cell analysis, high-throughput screening, sequencing, and microfluidics.
• Cost and productivity pressures encouraging outsourcing and platform-based discovery models.
• Supportive regulatory outlook for biologics and precision medicine across major European markets.

Major Challenges

• Limited availability of high-quality, standardized datasets to fully train and validate AI-driven discovery models.
• High capital and operational costs associated with advanced discovery platforms and digital infrastructure.
• Complexity in intellectual property ownership for AI-designed antibodies and shared datasets.
• Regulatory ambiguity around validation, reproducibility, and approval pathways for AI-enabled discovery outputs.
• Fragmentation across service providers and technology platforms, making vendor selection and benchmarking difficult.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Regulatory Landscape / Compliance
  • 1.1.1 E.U.
    • 1.1.1.1 Germany
    • 1.1.1.2 France
    • 1.1.1.3 Italy
• 1.2 Pricing Analysis
  • 1.2.1 By Product
  • 1.2.2 By Region
• 1.3 Supply Chain Analysis
• 1.4 Value Chain Analysis
• 1.5 Patent Analysis
  • 1.5.1 By Country
  • 1.5.2 By Company
• 1.6 Market Dynamics
  • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
  • 1.6.2 Market Trends
    • 1.6.2.1 Shift toward Fully Human and Humanized Antibodies
    • 1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
    • 1.6.2.3 Growing Role of Contract Research Organizations (CROs)
  • 1.6.3 Market Drivers
    • 1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
    • 1.6.3.2 Increasing Prevalence of Chronic Diseases
  • 1.6.4 Market Challenges
    • 1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
    • 1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 By Offering
  • 2.2.5 By Technology
  • 2.2.6 By Country
    • 2.2.6.1 U.K.
      • 2.2.6.1.1 By Offering
      • 2.2.6.1.2 By Technology
    • 2.2.6.2 Germany
      • 2.2.6.2.1 By Offering
      • 2.2.6.2.2 By Technology
    • 2.2.6.3 France
      • 2.2.6.3.1 By Offering
      • 2.2.6.3.2 By Technology
    • 2.2.6.4 Italy
      • 2.2.6.4.1 By Offering
      • 2.2.6.4.2 By Technology
    • 2.2.6.5 Spain
      • 2.2.6.5.1 By Offering
      • 2.2.6.5.2 By Technology
    • 2.2.6.6 Sweden
      • 2.2.6.6.1 By Offering
      • 2.2.6.6.2 By Technology
    • 2.2.6.7 Netherlands
      • 2.2.6.7.1 By Offering
      • 2.2.6.7.2 By Technology
    • 2.2.6.8 Rest-of-Europe
      • 2.2.6.8.1 By Offering
      • 2.2.6.8.2 By Technology

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Product Mapping
  • 3.1.1 By Company
  • 3.1.2 By Offering
  • 3.1.3 By Technology
• 3.2 Pipeline Analysis
• 3.3 Company Profiles
  • 3.3.1 Genmab A/S
    • 3.3.1.1 Overview
    • 3.3.1.2 Top Products/Product Portfolio
    • 3.3.1.3 Top Competitors
    • 3.3.1.4 Target Customers
    • 3.3.1.5 Key Personal
    • 3.3.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast